Quarterly Revenue Growth Exceeded Expectations
Q4 2025 total revenue of $393.9 million, up 11% year-over-year on a GAAP basis and up 10% year-over-year on a constant currency basis; organic constant currency growth in Q4 was 6.6%, modestly above guidance.
Strong Profitability and Margin Expansion
Q4 non-GAAP operating margin increased 138 basis points year-over-year to 21.0%; gross margin in Q4 was 54.5%, up 103 basis points year-over-year and the highest quarterly gross margin in company history.
Earnings and Cash Flow Outperformance
Q4 non-GAAP EPS grew 12% year-over-year and exceeded the high end of guidance; Q4 free cash flow was a company quarterly record of $74 million, up 13% year-over-year.
Strong Full-Year 2025 Financial Results
Full year 2025 constant currency revenue growth of 11%; non-GAAP operating margin of 20.3%, a 131 basis point increase year-over-year; nearly $216 million of free cash flow in 2025, up 16% year-over-year — all exceeding the high end of original 2025 guidance (10% revenue growth, 19.7% margin, $150M FCF).
Product and Segment Strength Driving Growth
Cardiovascular segment +9% in Q4 and Endoscopy +15% in Q4. Cardiac Intervention product sales increased 21% (12% organic excluding acquisitions); Peripheral Intervention sales increased 13% with radar localization and delivery systems >25% year-over-year, contributing materially to PI growth.
Healthy Balance Sheet and Leverage
As of Dec 31, 2025: cash and cash equivalents $446.4 million, total debt $747.5 million, available borrowing capacity ~ $697 million; adjusted net leverage ratio was 1.6x.
2026 Guidance Reflects Continued Profitability and Cash Generation
2026 guidance: GAAP revenue growth 6%–8% (constant currency 5%–7%); organic constant currency growth ~4.5%–6% excluding expected inorganic contributions; non-GAAP diluted EPS $4.01–$4.15 (up 5%–8%); non-GAAP operating margin expansion of ~36–76 basis points; free cash flow at least $200 million and CapEx ~ $90 million.
Strategic Progress and Platform Approach
CEO transition and new leadership/operating structure completed; platform alignment (foundational vs therapeutic products) clarified; continued multi-year CGI targets reiterated: organic revenue CAGR 5%–7%, non-GAAP operating margin 20%–22%, cumulative free cash flow > $400M through 2026.